Update in adrenocortical carcinoma - Abstract

Adrenocortical carcinoma (ACC) is an orphan malignancy that has attracted increasing attention during the last decade.

Here we provide an update on advances in the field since our last review published in this journal in 2006.The Wnt/β-catenin pathway and insulin-like growth factor-2 (IGF-2) signaling have been confirmed as frequently altered signaling pathways in ACC but recent data suggest that they are probably not sufficient for malignant transformation. Thus, major players in the pathogenesis are still unknown.For diagnostic workup, comprehensive hormonal assessment and detailed imaging are required, because in most ACCs evidence for autonomous steroid secretion can be found and computed tomography or magnetic resonance imaging (if necessary combined with functional imaging) can differentiate benign from malignant adrenocortical tumors. Surgery is potentially curative in localized tumors. Thus, we recommend to perform complete resection including lymphadenectomy by an expert surgeon. The pathology report should demonstrate the adrenocortical origin of the lesion (e.g. by SF1 staining) and provide Weiss score, resection status and quantitation of the proliferation marker Ki67 to guide further treatment. Even after complete surgery recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists whether all patients benefit from this therapy.In advanced ACC, mitotane is still standard of care. Based on the FIRM-ACT trial, mitotane plus etoposide, doxorubicin, and cisplatin is now the established first-line cytotoxic therapy. However, most patients will experience progress and require salvage therapies. Thus, new treatment concepts are urgently needed. The ongoing international efforts including comprehensive "omic approaches" and next generation sequencing will improve our understanding of the pathogenesis and hopefully lead to better therapies.

Written by:
Fassnacht M, Kroiss M, Allolio B.   Are you the author?
Dept. of Internal Medicine IV, Clinical Endocrinology, Hospital of the University of Munich, Munich, Germany; Dept. of Internal Medicine I, Endocrine and Diabetes Unit, University Hospital, University of Würzburg, Würzburg, Germany.

Reference: J Clin Endocrinol Metab. 2013 Sep 30. Epub ahead of print.
doi: 10.1210/jc.2013-3020


PubMed Abstract
PMID: 24081734

UroToday.com Adrenal and Kidney Conditions Section

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe